



## **Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023**

April 26, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 26, 2023-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023.

In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 3, 2023, to discuss the Company's financial results and provide a corporate update.

The conference call may be accessed via this link: <https://register.vevent.com/register/BI75fb53c225a648b486e50d922b166468>

A live webcast of the conference call will be available in the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investors.deciphera.com/events-presentations>. A replay will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

### **About Deciphera Pharmaceuticals**

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera's switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit [www.deciphera.com](http://www.deciphera.com) and follow us on LinkedIn and Twitter (@Deciphera).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230426005051/en/): <https://www.businesswire.com/news/home/20230426005051/en/>

### **Investor Relations:**

Maghan Meyers  
Argot Partners  
[Deciphera@argotpartners.com](mailto:Deciphera@argotpartners.com)  
212-600-1902

### **Media:**

David Rosen  
Argot Partners  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)  
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.